Home › Funds › Catalio Capital Management, LP › SNDX
Catalio Capital Management, LP position in SNDX
SYNDAX PHARMACEUTICALS INC · Health Care
Catalio Capital Management, LP reported holding 1,215,698 shares of SNDX (SYNDAX PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$26.6M, representing 4.99% of its reported portfolio and ranking #5 among its reported holdings. Catalio Capital Management, LP has disclosed SNDX holdings in 6 of the last 6 reported quarters, going back to Q1 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Catalio Capital Management, LP's SNDX position evolved
Catalio Capital Management, LP first disclosed a stake in SNDX in Q1 2025 at 1,733,701 shares (US$21.3M). The position peaked in Q2 2026 at 1,215,698 shares, worth US$26.6M. Across 6 filings, Catalio Capital Management, LP increased the stake 2 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,215,698 shares valued at US$26.6M — an increase of 172,028 shares quarter over quarter.. Notable position changes include a 26% trim in Q4 2025 (shares rose 11% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2025 | 1.73M | $21.30M | New |
| Q2 2025 | 2.10M | $19.71M | Add |
| Q3 2025 | 1.61M | $24.84M | Reduce |
| Q4 2025 | 1.20M | $25.14M | Reduce |
| Q1 2026 | 1.04M | $24.38M | Reduce |
| Q2 2026 | 1.22M | $26.58M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SNDX and 13F data
SNDX (SYNDAX PHARMACEUTICALS INC) is a Health Care company. 42 other funds we track also report a position in SNDX — the largest reported positions include Kynam Capital Management, LP (US$176.0M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$82.6M), Eversept Partners, LP (US$61.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SNDX
- Kynam Capital Management, LP 8.05M sh · $175.99M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 3.78M sh · $82.63M · Q2 2026
- Eversept Partners, LP 2.80M sh · $61.17M · Q2 2026
- KINGDON CAPITAL MANAGEMENT, L.L.C. 2.50M sh · $54.65M · Q2 2026
- Elmind Capital, LP 1.85M sh · $40.55M · Q2 2026
- Soleus Capital Management, L.P. 1.63M sh · $35.59M · Q2 2026
- ORBIMED ADVISORS LLC 1.54M sh · $33.71M · Q2 2026
- MPM BioImpact LLC 1.33M sh · $29.15M · Q2 2026
- Aisling Capital Management LP 1.32M sh · $28.79M · Q2 2026
- Prosight Management, LP 1.20M sh · $26.23M · Q2 2026
- Trails Edge Capital Partners, LP 1.11M sh · $24.26M · Q2 2026
- SPHERA FUNDS MANAGEMENT LTD. 1.01M sh · $22.18M · Q2 2026
More on Catalio Capital Management, LP
FAQ
How long has Catalio Capital Management, LP held SNDX?
Catalio Capital Management, LP has disclosed SNDX holdings in 6 of the last 6 reported quarters, going back to Q1 2025.
What is Catalio Capital Management, LP's current position in SNDX?
As of Q2 2026, Catalio Capital Management, LP holds 1.22M shares of SNDX (SYNDAX PHARMACEUTICALS INC), valued at $26.58M, representing 4.99% of its reported portfolio and ranking #5.
Has Catalio Capital Management, LP been buying or selling SNDX?
In the latest 13F filing (Q2 2026), Catalio Capital Management, LP increased its position in SNDX. The position peaked in Q2 2026 at 1.22M shares.
Which other funds hold SNDX?
Other major institutional holders of SNDX include Kynam Capital Management, LP, DEERFIELD MANAGEMENT COMPANY, L.P., Eversept Partners, LP, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.